Polypharmacology in a Single Drug: Multitarget Drugs
Abstract
Polypharmacology offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases. It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these. Polypharmacology can involve combinations and/or multitarget drugs (MTD). Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations. This review article focuses on MTDs from a medicinal chemistry perspective. I will explore their use in current clinical practice, their likely application in the future, and the challenges to be overcome to achieve this goal. Keywords: Multifactorial diseases, Combination therapy, multitarget drug discovery, network pharmacology, multitargetdirected ligands, designed multiple ligands
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Adherence to a complex therapy is unlikely for forgetful AD patients and their caregivers.
“Both are critical issues in AD: (a) adherence to a complex therapy is unlikely for forgetful AD patients and their caregivers; (b) coexistence of chronic disease, polypharmacy, and impaired organ functions makes geriatric population particularly susceptible to DDIs.49”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [49]
Coexistence of chronic disease, polypharmacy, and impaired organ functions makes the geriatric population particularly susceptible to drug-drug interactions.
“Both are critical issues in AD: (a) adherence to a complex therapy is unlikely for forgetful AD patients and their caregivers; (b) coexistence of chronic disease, polypharmacy, and impaired organ functions makes geriatric population particularly susceptible to DDIs.49”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [49]
The single-molecule pharmacokinetic profile of hybrids may allow avoidance of drug-drug interactions (DDI), which occur more frequently in AD patients due to coexistence of chronic disease, therapies, and impaired organ functions.
“Furthermore, the single-molecule pharmacokinetic profile of hybrids, from administration to secretion, may allow to avoid DDI, that occur more frequently in AD patients, because of the coexistence of chronic disease, therapies, and impaired organ functions.49”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [49]
Cited by
Sorted by citations
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popović-Nikolić, M. R., Nikolic, K. M., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 730 · see citing works
“In parallel, we have learned that molecules hitting more than one target may possess in principle a safer profile compared to single-targeted ones [1, 2].”
BackgroundSelf-citationPolypharmacology – Foe or Friend?
Peters, J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 477 · see citing works
Drug combination therapy increases successful drug repositioning
Sun, W., Sanderson, P. E. J., & Zheng, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.05.015 · Cited by 438 · see citing works
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 384 · see citing works
Self-citationPotential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases
Makhoba, X. H., Viegas, C., Mosa, R. A., Viegas, F. P. D., & Pooe, O. J. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 333 · see citing works
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 307 · see citing works
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260 · see citing works
Sulfonamide derivatives as multi-target agents for complex diseases
Apaydın, S., & Török, M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.041 · Cited by 262 · see citing works
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179 · see citing works
Self-citationChronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems
Plachá, D., & Jampílek, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010064 · Cited by 177 · see citing works
Nepovimová, E., Uliassi, E., Korábečný, J., Peña‐Altamira, E., Samez, S., Pesaresi, A., Garcia, G. E., Bartolini, M., Andrisano, V., Bergamini, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010804 · Cited by 154 · see citing works
Self-citation2,3-Dihydroquinazolin-4(1 H )-one as a privileged scaffold in drug design
Badolato, M., Aiello, F., & Neamati, N. (2018) · RSC Advances · doi:10.1039/c8ra02827c · Cited by 143 · see citing works
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Wen, S., Wang, G., Zhang, Y., Bu, F., Zhang, S., Miller, D. D., Li, W., Ouyang, L., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00100 · Cited by 149 · see citing works
Gontijo, V. S., Viegas, F. P. D., Ortiz, C. J. C., Silva, M. D. F., Damásio, C. M., Rosa, M. C., Campos, T. G., Couto, D. S., Dias, K. S. T., & Viegas, C. (2019) · Current Neuropharmacology · doi:10.2174/1385272823666191021124443 · Cited by 147 · see citing works
“To date, approaches in drug design are still based in the reductionist concept of “one gene-one drug-one target”, leading to a linear model for a clinical effect, by which a single molecule binds selectively to a single molecular target resulting in a desired therapeutical response and undesired adverse effects [54-56…”
BackgroundCaffeic acid derivatives, analogs and applications: a patent review (2009 – 2013)
Silva, T., Oliveira, C., & Borges, F. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.959492 · Cited by 132 · see citing works
“The exploration of this novel drug-design paradigm might result in the development of more efficient molecules [70,71].”
BackgroundAnti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018)
Mishra, P., Kumar, A., & Panda, G. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.025 · Cited by 128 · see citing works
Advances in the treatment of Chagas disease: Promising new drugs, plants and targets
García‐Huertas, P., & Cardona-Castro, N. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112020 · Cited by 126 · see citing works
Harnessing Polypharmacology with Medicinal Chemistry
Bolognesi, M. L. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00039 · Cited by 129 · see citing works
Self-citationTacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease
Jerábek, J., Uliassi, E., Guidotti, L., Korábečný, J., Soukup, O., Šepsová, V., Hrabinová, M., Kuča, K., Bartolini, M., Peña‐Altamira, E., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.048 · Cited by 113 · see citing works
Self-citationPrati, F., Cavalli, A., & Bolognesi, M. (2016) · Molecules · doi:10.3390/molecules21040466 · Cited by 110 · see citing works
“Furthermore, simplifying the therapeutic regimen with a single multitarget agent could add significant value for dementia patients and their caregivers who have inherent difficulty with compliance and therapy adherence [8].”
BackgroundSelf-citationPolypharmacology: The Rise of Multitarget Drugs over Combination Therapies
Rosini, M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.25 · Cited by 103 · see citing works
Wang, T., Liu, X.-H., Guan, J. Z., Ge, S., Wu, M., Lin, J., & Yang, L.-R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.076 · Cited by 93 · see citing works
Rosini, M., Simoni, E., Minarini, A., & Melchiorre, C. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1250-1 · Cited by 94 · see citing works
Pogodin, P. V., Lagunin, A. A., Filimonov, D. A., & Poroikov, V. (2015) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2015.1078407 · Cited by 91 · see citing works
“Multi-target drug action is also con fi rmed in a number of publications [9 – 11] and by the DrugBank data [12], indicating that most drugs interact with two or more targets.”
BackgroundGunter, N. V., Teh, S. S., Lim, Y. M., & Mah, S. H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.594202 · Cited by 91 · see citing works
“Thus, the concept of polypharmacology which aims to develop single drugs that recognize multiple molecular targets emerged rapidly as a popular strategy in drug design and development (Bolognesi, 2013; Makhoba et al., 2020).”
BackgroundÇınar, R., Gochuico, B. R., Iyer, M. R., Jourdan, T., Yokoyama, T., Park, J. K., Coffey, N. J., Pri‐Chen, H., Szanda, G., Liu, Z., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92281 · Cited by 90 · see citing works
“Polypharmacology is an emerging strategy that involves the use of a single chemical entity to target multiple therapeutic pathways (6).”
BackgroundZhang, K., Lai, F., Lin, S., Ji, M., Zhang, J., Zhang, Y., Jin, J., Fu, R., Wu, D., Tian, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00390 · Cited by 99 · see citing works
Çınar, R., Iyer, M. R., Liu, Z., Cao, Z., Jourdan, T., Erdélyi, K., Godlewski, G., Szanda, G., Liu, J., Park, J. K., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.87336 · Cited by 86 · see citing works
“simultaneously hitting multiple therapeutic targets (2).”
Dias, K. S. T., de Paula, C. T., dos Santos, T., Souza, I. N. D. O., Boni, M. S., Guimarães, M. J. R., da Silva, F. M. R., Castro, N. G., Neves, G. A., Veloso, C. C., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.02.043 · Cited by 83 · see citing works
Multitarget Strategies in Alzheimer’S Disease: Benefits and Challenges on the Road to Therapeutics
Rosini, M., Simoni, E., Caporaso, R., & Minarini, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0003 · Cited by 78 · see citing works
Prati, F., Uliassi, E., & Bolognesi, M. L. (2014) · MedChemComm · doi:10.1039/c4md00069b · Cited by 77 · see citing works
Self-citationViayna, E., Sabaté, R., & Muñoz‐Torrero, D. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990139 · Cited by 76 · see citing works
“…and the effectiveness of single-target therapies, and boosts the use of phenotypic in vivo tests and the development of multi-target therapies, particularly multi-target single-molecule drugs, i.e. the so-called multi-target drugs, multiple ligands or multi-target-directed ligands [40] [41].”
BackgroundPharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders
Gupta, R. V., Ambasta, R. K., & Kumar, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117278 · Cited by 79 · see citing works
Gupta, P. S. S., Bhat, H. R., Biswal, S., & Rana, M. K. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.114375 · Cited by 67 · see citing works
Polypharmacological drug actions of recently FDA approved antibiotics
Wetzel, C., Lonneman, M., & Wu, C. A. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112931 · Cited by 66 · see citing works
Polypharmacology of dopamine receptor ligands
Butini, S., Nikolic, K. M., Kassel, S., Brückmann, H., Filipić, S., Agbaba, D. D., Gemma, S., Brogi, S., Brindisi, M., Campiani, G., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.011 · Cited by 67 · see citing works
Chandrika, S. K., Haixiao, J., Naman, C. B., & Sajeevan, T. P. (2020) · Drug Development Research · doi:10.1002/ddr.21673 · Cited by 65 · see citing works
Marine natural products for multi-targeted cancer treatment: A future insight
Kumar, M. S., & Adki, K. M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.142 · Cited by 67 · see citing works
Synthesis and evaluation of novel dual BRD4/HDAC inhibitors
Amemiya, S., Yamaguchi, T., Hashimoto, Y., & Noguchi‐Yachide, T. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.04.043 · Cited by 66 · see citing works
Salinomycin and its derivatives – A new class of multiple-targeted “magic bullets”
Antoszczak, M., & Huczyński, A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.031 · Cited by 63 · see citing works
Li, Y., Wang, P., Li, X. X., Yu, C. Y., Yang, H. J., Zhou, J., Xue, W., Tan, J., & Zhu, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165737 · Cited by 59 · see citing works
“So far, several studies have been conducted to assess the applicability domain of both multi-target drug and combination product and to analyze their advantages over another [23,24].”
BackgroundA review on pharmacophoric designs of antiproliferative agents
Rana, A., Alex, J. M., Chauhan, M., Joshi, G., & Kumar, R. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-1196-5 · Cited by 58 · see citing works
“Various strategies have been adopted for combating above-mentioned problems via synergistic action and dose reduction involving either combining two pharmacophores, (2) using a dual pharmacophore in a single molecule, or (3) utilizing the multi-targeted pharmacophore approaches (Bolognesi, 2013).”
MethodKeri, R. S., Quintanova, C., Chaves, S., Silva, D. F., Cardoso, S. M., & Santos, M. A. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12633 · Cited by 56 · see citing works
“Accordingly, the current drug strategy has been based on the development of anti-Alzheimer agents with multiple potencies (3,4), such as the inhibition of AChE and amyloid-beta (Ab) peptide aggregation as well as antioxidant activity.”
BackgroundDocking Studies for Multi-Target Drugs
Scotti, L., Mendonça, F. J. B., Ishiki, H. M., Ribeiro, F. F., Singla, R. K., Barbosa‐Filho, J. M., da Silva, M. S., & Scotti, L. (2015) · Current Drug Targets · doi:10.2174/1389450116666150825111818 · Cited by 58 · see citing works
Dual-target inhibitors based on acetylcholinesterase: Novel agents for Alzheimer's disease
Zhao, X., Hu, Q., Wang, X., Li, C., Chen, X., Zhao, D. H., Qiu, Y., Xu, H., Wang, J., Ren, L., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116810 · Cited by 56 · see citing works
Doadrio, A. L., Sánchez-Montero, J. M., Doadrio, J. C., et al. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.11.002 · Cited by 55 · see citing works
“Thus, medications containing several active components in a single dose (Bender et al., 2006; Bolognesi, 2013; Petrelli and Valabrega, 2009) that for hypertension treatment is called polypill (Lonn et al., 2010; Sleight et al., 2006; TIP Study, 2009).”
BackgroundRecent Advances in the Rational Drug Design Based on Multi-target Ligands
Yang, T., Sui, X., Yu, B., Shen, Y., & Cong, H. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200102120652 · Cited by 54 · see citing works
What are the challenges with multi-targeted drug design for complex diseases?
Zięba, A., Stępnicki, P., Matosiuk, D., & Kaczor, A. A. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2072827 · Cited by 55 · see citing works
Belluti, F., Uliassi, E., Veronesi, G., Bergamini, C., Kaiser, M., Brun, R., Viola, A., Fato, R., Michels, P. A. M., Krauth‐Siegel, R. L., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300399 · Cited by 53 · see citing works
Self-citationNew Approaches to Treating Alzheimer's Disease
Zheng, H., Fridkin, M., & Youdim, M. B. H. (2015) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s13210 · Cited by 52 · see citing works
2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile
Prati, F., Bergamini, C., Molina, M. T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00748 · Cited by 49 · see citing works
Self-citationHajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 55 · see citing works
Peña‐Altamira, E., Petralla, S., Massenzio, F., Virgili, M., Bolognesi, M. L., & Monti, B. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00175 · Cited by 46 · see citing works
“Considering the multifactorial nature of cognitive impairment in aging, especially in AD, it is evident that a multitarget-based approach is essential to address this complex condition (Bolognesi, 2013).”
BackgroundSelf-citationMangiatordi, G. F., Intranuovo, F., Delre, P., Abatematteo, F. S., Abate, C., Niso, M., Creanza, T. M., Ancona, N., Stefanachi, A., & Contino, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01357 · Cited by 49 · see citing works
Plazas, E., Casoti, R., Murillo, M. C. Á., Costa, F. B. D., & Suárez, L. E. C. (2019) · Phytochemistry · doi:10.1016/j.phytochem.2019.112128 · Cited by 45 · see citing works
Detecting similar binding pockets to enable systems polypharmacology
Duran‐Frigola, M., Siragusa, L., Ruppin, E., Barril, X., Cruciani, G., & Aloy, P. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005522 · Cited by 40 · see citing works
Rosado-Solano, D. N., Barón-Rodríguez, M. A., Sanabria, P., et al. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b01067 · Cited by 41 · see citing works
Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors
Ma, H., Huang, B., & Zhang, Y. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.004 · Cited by 43 · see citing works
“For these complex diseases, acting on a single target might be inadequate to achieve satisfactory therapeutic effects [8,9].”
BackgroundPrajapati, R., Seong, S. H., Park, S. E., Paudel, P., Jung, H. A., & Choi, J. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-02843-6 · Cited by 42 · see citing works
Wu, S., Huang, Y., Wang, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02026 · Cited by 41 · see citing works
Quintanova, C., Keri, R. S., Marques, S. M., G-Fernandes, M., Cardoso, S. M., Serralheiro, M. L., & Santos, M. A. (2015) · MedChemComm · doi:10.1039/c5md00236b · Cited by 40 · see citing works
Pérez-Areales, F. J., Turcu, A. L., Barniol‐Xicota, M., Pont, C., Pivetta, D., Espargaró, A., Bartolini, M., Simone, A. D., Andrisano, V., Pérez, B., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.051 · Cited by 43 · see citing works
“Even though the design and development of multitarget drugs can be very challenging [12], it has some clear advantages over multiple-medication therapies, such as simpler dose regimens and improved patient compliance, simpler pharmacokinetics and lack of drug‒drug interactions, and simpler clinical development, among…”
Thioamides in medicinal chemistry and as small molecule therapeutic agents
Huang, G., Cierpicki, T., & Grembecka, J. E. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116732 · Cited by 38 · see citing works
Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part I: Curcumin
Martino, R. M. C. D., Luppi, B., Bisi, A., Gobbi, S., Rampa, A., Abruzzo, A., & Belluti, F. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1276566 · Cited by 36 · see citing works
“Drug combinations, based on the coadministration of two or more drugs acting by common or different mechanisms of action, allowed obtaining additive or synergistic therapeutic effects [29-31].”
BackgroundAntiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 37 · see citing works
Human Disease and Drug Pharmacology, Complex as Real Life
Viayna, E., Sola, I., Pietro, O. D., & Muñoz‐Torrero, D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130002 · Cited by 36 · see citing works
“These strategies will be only briefly discussed herein, as they will be presented in more detail in other articles of this issue [94-104].”
BackgroundSimone, A. D., Russo, D., Ruda, G. F., Micoli, A., Ferraro, M., Martino, R. M. C. D., Ottonello, G., Summa, M., Armirotti, A., Bandiera, T., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01578 · Cited by 34 · see citing works
Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Sequeira, L., Benfeito, S., Fernandes, C., Gaspar, A., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Borges, F., & Chavarria, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060708 · Cited by 36 · see citing works
“Therefore, drugs that can simultaneously manipulate multiple targets may provide therapeutic benefits in AD and PD diseases due to their multifactorial nature and complexity [296].”
BackgroundRecent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders
Jůza, R., Musílek, K., Mezeiová, E., Soukup, O., & Korábečný, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21923 · Cited by 33 · see citing works
Farag, A. K., Hassan, A. H. E., Jeong, H., Kwon, Y., Choi, J. G., Oh, M. S., Park, K. D., Kim, Y. K., & Roh, E. J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.057 · Cited by 34 · see citing works
Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90)
Bonanni, D., Citarella, A., Moi, D., Pinzi, L., Bergamini, E., & Rastelli, G. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210902145102 · Cited by 33 · see citing works
Rosini, M., Simoni, E., Bartolini, M., Soriano, E., Marco, J. L., Andrisano, V., Monti, B., Windisch, M., Hutter‐Paier, B., McClymont, D. W., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300263 · Cited by 31 · see citing works
Self-citationEpidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review
Wang, C., Zhang, Y., Zhang, T., Xu, J., Yan, S., Liang, B., & Xing, D. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127440 · Cited by 31 · see citing works
Berishvili, V. P., Voronkov, A. E., Radchenko, E. V., & Palyulin, V. A. (2018) · Molecular Informatics · doi:10.1002/minf.201800030 · Cited by 31 · see citing works
Multi-Target β-Protease Inhibitors from Andrographis paniculata: In Silico and In Vitro Studies
Panche, A. N., Chandra, S., & Diwan, A. (2019) · Plants · doi:10.3390/plants8070231 · Cited by 30 · see citing works
Mangione, W., & Samudrala, R. (2019) · Molecules · doi:10.3390/molecules24010167 · Cited by 26 · see citing works
“Coupling this with the finding that there 209 is a minimum number of proteins required to reach optimal benchmarking accuracies (Figure 2), which 210 was also observed by us previously [15,16], drugs should realistically be described in the context of 211 their multitarget nature, treating both small molecule compound…”
BackgroundMulti-targeted drug design strategies for the treatment of schizophrenia
Stępnicki, P., Kondej, M., Koszła, O., Żuk, J., & Kaczor, A. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1816962 · Cited by 28 · see citing works
Feng, F., Zhang, W., Chai, Y., Guo, D., & Chen, X. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.115107 · Cited by 29 · see citing works
Castro, M. A., Gamito, A. M., Tangarife-Castaño, V. J., Roa-Linares, V. C., del Corral, J. M. M., Mesa-Arango, A. C., Betancur-Galvis, L. A., Francesch, A., & Feliciano, A. S. (2014) · RSC Advances · doi:10.1039/c4ra11726c · Cited by 28 · see citing works
Systematic Investigation of Dual-Target-Directed Ligands
Lembo, V., & Bottegoni, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00838 · Cited by 29 · see citing works
Pravin, N., & Jóźwiak, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116085 · Cited by 29 · see citing works
Prati, F., Bartolini, M., Simoni, E., Simone, A. D., Pinto, A., Andrisano, V., & Bolognesi, M. L. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.09.091 · Cited by 27 · see citing works
Self-citationCanale, V., Grychowska, K., Kurczab, R., Ryng, M., Keeri, A. R., Satała, G., Olejarz‐Maciej, A., Koczurkiewicz, P., Drop, M., Blicharz-Futera, K., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112765 · Cited by 28 · see citing works
In vitro activity of non-antibiotic drugs against Staphylococcus aureus clinical strains
Boyd, N. K., Lee, G. C., Teng, C., & Frei, C. R. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.09.003 · Cited by 24 · see citing works
Zhu, C., Yang, Y., Li, X., Chen, X., Lin, X., & Wu, X. (2022) · Nano Research · doi:10.1007/s12274-021-4066-8 · Cited by 26 · see citing works
cando.py: Open Source Software for Predictive Bioanalytics of Large Scale Drug–Protein–Disease Data
Mangione, W., Falls, Z., Chopra, G., & Samudrala, R. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00110 · Cited by 25 · see citing works
Bottegoni, G., Veronesi, M., Bisignano, P., Kacker, P., Favia, A. D., & Cavalli, A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500521 · Cited by 25 · see citing works
Pasieka, A., Panek, D., Jończyk, J., Godyń, J., Szałaj, N., Latacz, G., Tabor, J., Mezeiová, E., Chantegreil, F., Dias, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113397 · Cited by 30 · see citing works
De novo generation of dual-target ligands using adversarial training and reinforcement learning
Lu, F., Li, M., Min, X., Li, C., & Zeng, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab333 · Cited by 28 · see citing works
Gilberg, E., Gütschow, M., & Bajorath, J. (2019) · ACS Omega · doi:10.1021/acsomega.8b03481 · Cited by 25 · see citing works
Zajdel, P., Grychowska, K., Mogilski, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00224 · Cited by 24 · see citing works
“26,27 The molecular framework for developing compounds that target both receptors arises from the structural similarity of pyrroloquinoxaline I , a 5-HT 3 R ligand, 28 and CPPQ, a pyrroloquinoline-based 5-HT 6 R antagonist (Figure 2).”
Simone, A. D., Bartolini, M., Baschieri, A., Apperley, K. Y.-P., Chen, H. H., Guardigni, M., Montanari, S., Kobrlová, T., Soukup, O., Valgimigli, L., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.058 · Cited by 25 · see citing works
Blaschke, T., Miljković, F. N., & Bajorath, J. (2019) · ACS Omega · doi:10.1021/acsomega.9b00492 · Cited by 23 · see citing works
Identifying Promiscuous Compounds with Activity against Different Target Classes
Feldmann, C., Miljković, F. N., Yonchev, D., & Bajorath, J. (2019) · Molecules · doi:10.3390/molecules24224185 · Cited by 23 · see citing works
Mondal, S., Vashi, Y., Ghosh, P., Roy, D., Barthakur, M., Kumar, S., & Iyer, P. K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00387 · Cited by 22 · see citing works
Genovese, M., Imperatore, C., Casertano, M., Aiello, A., Balestri, F., Piazza, L., Menna, M., CORSO, A. D., & Paoli, P. (2021) · Marine Drugs · doi:10.3390/md19100535 · Cited by 24 · see citing works
Combined drug triads for synergic neuroprotection in retinal degeneration
Maneu, V., Lax, P., de Diego, A. M. G., Cuenca, N., & de Diego, A. M. G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112911 · Cited by 23 · see citing works
Tang, H., Liang, Y., Shen, H., Cai, S., Yu, M., Fan, H., Ding, K., & Wang, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106112 · Cited by 27 · see citing works
One Drug for Multiple Targets: A Computational Perspective
Méndez‐Lucio, O., Naveja, J. J., Vite‐Caritino, H., Prieto-Martínez, F. D., & Medina‐Franco, J. L. (2017) · Journal of the Mexican Chemical Society · doi:10.29356/jmcs.v60i3.100 · Cited by 35 · see citing works
Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors
Dong, Y., Hu, H., Sun, Y., Qin, M., Gong, P., Hou, Y., & Zhao, Y. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127610 · Cited by 23 · see citing works
- Authors
- L. Bolognesi, M.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-03-01
- Volume
- 20
- Issue
- 13
- Pages
- 1639-1645
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2329046360
- Cited by
- 230
- References
- 0
- Citations by year
- 2026: 15 · 2025: 7 · 2024: 23 · 2023: 11 · 2022: 27 · 2021: 23 · 2020: 35 · 2019: 19 · 2018: 12 · 2017: 16 · 2016: 13 · 2015: 13 · 2014: 9 · 2013: 7
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- polypharmacology, multi-target drugs, multi-target drug discovery, combination therapy, network pharmacology, multi-target-directed ligands, complex diseases
- MeSH terms
- Animals, Drug Combinations, Drug Resistance, Microbial, Pharmaceutical Preparations, Humans, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
